| 3D | three dimensional |
| ACDA | acid citrate dextrose solution |
| ADSC | Adipose-derived mesenchymal stem cells |
| Ang 1 | angiopoietin-1 |
| BCT | blood cell therapy |
| βIgH3 | factor-β-induced protein Ig-H3 |
| CE | European conformity |
| CEO | chief executive officer |
| EC | endothelial cells |
| FBA | fibrin bead assay |
| FBS | fetal bovine serum |
| GMP | good manufacturing practices |
| HA | hyaluronic acid |
| HGF | hepatocyte growth factor |
| HUVEC | human umbilical vein endothelial cells |
| IGFBP7 | insulin-like growth factor binding protein 7 |
| LP-PRP | leukocyte poor PRP |
| LR-PRP | leukocyte rich PRP |
| NHDF | normal human dermal fibroblasts |
| MDD | medical device directive |
| MDR | medical device regulation |
| MDSAP | medical device single audit program |
| MNC | mononuclear cells |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide |
| OA | osteoarthritis |
| Ph. Eur | European pharmacopeia |
| PPP | platelet poor plasma |
| PRP | platelet-rich plasma |
| PRP-HA | platelet-rich plasma combined with hyaluronic acid |
| PL | platelet lysates |
| SMA | smooth muscle actin |
| SPARC | secreted protein acidic and cysteine-rich |
| TGF-α | transforming growth factor alpha |
| USP | US pharmacopeia |